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Background: Low level of high density lipoprotein cholesterol (HDL-C) has high prevalence in the Tehran Lipid
and Glucose Study (TLGS) cohort. About 50% of the inter-individual variation in serum HDL-C levels is genetically
determined. Polymorphisms in cholesteryl ester transfer protein (CETP) and hepatic lipase (LIPC) genes have been
found to be associated with the metabolism and serum concentration of the HDL-C.
Objectives: To determine the association between Taq1B polymorphism in CETP gene and -514C/T polymorphism
in LIPC gene with serum lipid levels and lipid peroxidation in a subgroup of the TLGS population.
Results: Serum HDL-C level had significant association with CETP Taq1B polymorphism and B2B2 subjects had the
highest HDL-C levels compared to B2B1 and B1B1 genotypes (37.9 vs. 36.9 and 35.3 mg/dl, respectively; P = 0.01).
However, carriers of “B1” allele, in comparison to the non carriers (B2B2), had significantly lower levels of TC (200.1
vs. 215.2 mg/dl; P = 0.005), HDL-C (35.8 vs. 37.9 mg/dl; P = 0.009) and malondialdehyde MDA (4.5 vs. 5.0 nmol/mL;
P=0.031). Carriers of the “T” allele in -514C/T polymorphism in LIPC gene had higher means of HDL-C than non
carriers (37.7 vs. 35.7 mg/dl, P = 0.04). No other association was found between -514C/T polymorphism and any
other serum lipids or MDA level.
Conclusion: This study demonstrates the association between Taq1B and -514C/T polymorphisms in the CETP and
LIPC genes with the serum HDL-C levels.
Introduction
Coronary artery disease (CAD) and stroke are the lead-
ing causes of morbidity, mortality and disability in
industrialized countries, and the prevalence of these
diseases is increasing rapidly in developing countries[1].
Convincing clinical evidence has shown an association
between the incidence of CAD and low levels of HDL-C
[2,3]. Epidemiological studies have shown a 2-3%
increase in CAD risk for each 1 mg/dl decrease in
HDL-C level[4]. Angiographic and ultrasonographic data
also indicate that low levels of HDL-C are associated
with the risk and severity of CAD, carotid disease, and
postangioplasty restenosis [5,6].
Fat type and its percentage in diet, smoking, alcohol,
body mass index (BMI) and physical activity [7] all have
a role in determining individual HDL-C levels; however,
family studies suggest that about 50% of the inter-indivi-
dual variation in serum HDL-C levels is genetically
determined [8,9]. Polymorphisms in cholesteryl ester
transfer protein (CETP) [9,10] and hepatic lipase (LIPC)
[11,12] genes have been found to be associated with the
variations in the HDL-C concentration.
Cholesteryl Ester Transfer Protein (CETP) is a hydro-
phobic glycoprotein that circulates in plasma bound
mainly to HDL-C[13]. It promotes the redistribution of
cholesteryl esters, triglycerides, and, to a lesser extent,
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genome-wide association studies have reported that CETP
genotypes are associated with HDL-C levels more strongly
than any other loci across the genome [9,10].
The most studied CETP restriction fragment length
polymorphism (RFLP) has been the TaqIB (Rs708272) in
the 277th nucleotide of the first CETP intron [15]. The
less common “B2” allele (absence of the TaqIB restriction
site) has been associated with increased HDL-C levels
and decreased CETP activity and levels[16].
Hepatic lipase (HL) is a lipolytic enzyme that plays a
role in triglyceride hydrolysis, phospholipid lipolysis,
LDL-C remodeling and HDL-C metabolism[17]. HL
promotes the conversion of buoyant HDL2-C particles
to small and dense HDL3-C particles by remodeling tri-
glycerides and phospholipids[18]. This process may
induce cholesterol ester efflux from peripheral tissues to
the lipase containing tissues [19,20]. Therefore, HL is
not only a determinant of HDL-C cholesterol levels but
also may be an important element in reverse cholesterol
transport [21].
A common “C” to “T” substitution has been described in
nucleotide -514 in the promoter region of the hepatic
lipase gene. “T”, the less common allele of the -514C/T
polymorphism (rs1800588), is associated with decreased
plasma HL activity and increased HDL-C concentrations
in many populations [22-25]; some other studies, however,
have failed to demonstrate such an association [26-29].
Iran is considered a nation in nutritional, economic
and demographic transition with a growing number of
cases with cardiovascular disease and metabolic syn-
drome [30,31]. The Tehran Lipid and Glucose Study
(TLGS) is a large cohort study that explores the risk fac-
tors for non-communicable diseases among Tehran’s
population [30]. Result of the first phase of the TLGS
has shown HDL-C levels below 35 mg/L in 32% of adult
subjects [30]. In comparison, only 16-18% of men and
3-6% of women in the US have HDL-C levels below 35
mg/L [32,33]. The average HDL-C level of the TLGS
community, was also found to be lower than the popu-
lations in the US [34], Europe[35], and Turkey [36].
The objectives of the present study were to: (a) deter-
mine the frequency of CETP Taq1B and LIPC -514C/T
polymorphisms in a subgroup of the TLGS cohort; (b)
investigate the possible effect of genetic polymorphism
at these loci on the low HDL-C serum levels in this
population; and (c) explore the association between
these single nucleotide polymorphisms (SNPs) and lipid
peroxidation.
Materials and methods
This cross-sectional study was carried out in a sub-
population of the TLGS cohort. In brief, TLGS is a
large scale community based study with a population of
15,005 people that has been launched since 1999 in the
13
th district of Tehran, the capital of Iran [30]. More
details about the rationales and design of the TLGS
have been published elsewhere [37].
By random sampling, 203 men and 252 women aged
30 to 88, who were not on any lipid-lowering treatment,
were recruited for this study. The sex ratio of the sub-
jects was similar to the TLGS population. The Medical
Ethics Committee of the Research Institute for Endo-
crine Sciences at Shahid Beheshti University of Medical
Science has reviewed and approved the protocol of the
study. Besides, an informed written consent was
obtained from each subject. All participants were inter-
viewed and clinically examined by a qualified physician.
In each subject anthropometric variables such as weight,
height, waist and hip circumference, BMI and blood
pressure were also measured. More detail about the
methods used for these measurements has been pre-
viously reported [30,37]. SPSS program was used for
data entry and analysis. A fasting blood sample was
collected for each participant.
Laboratory measurements
Blood Sampling
After an overnight fast 8 mL blood sample was col-
lected. The serum was isolated by centrifugation (3000
rpm, 10 min, 4°C) and 4 aliquots of 1 mL were frozen
at −80°C for measurement of lipids and MDA level.
Lipids
Serum concentrations of TC and TG were determined
through enzymatic colorimetric assay (TC & TG Kit, Pars
Azmoun, Iran). HDL-C was also measured by precipitat-
ing-enzymatic colorimetric assay after precipitation of the
apo B-containing lipoproteins with phosphotungistic acid
(Pars Azmon Kits, Iran). LDL-C was calculated by the
Friedewald formula [38]. LDL-C calculation was ignored if
TG concentration was >400 mg/dl. Assay performance
was monitored with an interval of every 20 tests using the
lipid control serum, Precinorm [normal range] and Preci-
path [pathologic range] wherever applicable (Boehringer
Mannheim, Germany; cat. no. 1446070 for Precinorm and
171778 for Precipath). Lipid standard (C.f.a.s, Boehringer
Mannheim, Germany; cat. no. 759350) was used to cali-
brate the Selectra 2 auto-analyzer on all days of laboratory
analysis. All samples were analyzed when internal quality
controls were in the acceptable range. Inter- and intra-
assay coefficients of variation were 2 and 1.1% for TC and
2.1 and 1.3% for TGs, respectively.
Concentration of serum MDA - as a marker for lipid
peroxidation - was measured by its reactivity with thio-
barbituric acid[39] (Cayman’s TBARS Assay Kit - USA -
Catalogue No. 10009055).
Kashani Farid et al. Lipids in Health and Disease 2010, 9:96
http://www.lipidworld.com/content/9/1/96
Page 2 of 7DNA Extraction
Blood leukocytes purification and DNA extraction from
it was carried out as described by Truett, et al.[40]. The
concentration and purity of the extracted DNA were
determined by spectrometry. DNA samples were then
stored in aliquot at “-20°C” for future analysis.
CETP Genotyping
A fragment of 535 bp in intron 1 of the CETP gene was
amplified by polymerase chain reaction (PCR) in a DNA
Thermal Cycler (Hybaid co. England) as described by
Ordovas et al [41] with the use of oligonucleotide primers
(forward 5’-CACTAGCCCAGAGAGAGGAGTGCC-3’,
Reverse: 5’-CTGAGCCCAGCCGCACACTAAC-3’). The
PCR was performed by using 100 ng genomic DNA in a
final volume of 50 mL containing 40 pmol of each oligo-
nucleotide, 0.2 mmol/L dNTPs, 1.5 mmol/L MgCl2,
10 mmol/L Tris, pH 8.4, and 0.25 U of Taq polymerase.
(Fermentas Co. Canada), 0.75 mmol/L MgCl2 and
10 mmol/L Tris, pH 8.4. After initial denaturation at 96°C
for 5 min, PCR was carried out for 35 cycles, each one
comprised of denaturation at 95°C for 45 seconds, anneal-
ing at 65°C for 1 min, and extension at 72°C for 1 min,
with a final extension time of 5 min at 72°C. The PCR pro-
ducts were subjected to restriction enzyme analysis by
digestion with TaqI restriction endonucleases (Fermentase
Canada) at 65°C for 2 h. The fragments were separated by
electrophoresis on a 1.5% agarose gel. After electrophor-
esis, the gel was treated with ethidium bromide for
20 min, and DNA fragments were visualized by UV illumi-
nation. The resulting fragments were 174 and 361 bp for
the “B1” allele and 535 bp for the uncut “B2” allele.
LIPC Genotype
Hepatic lipase genotyping was performed as described
by Guerra et al [11]. A 285-bp sequence of the LIPC
gene was amplified by polymerase chain reaction (PCR)
by using oligonucleotide primers 5’-TCTAGGAT-
CACCTCTCAATGGGTCA-3’ and 5’-GGTGGCTT
CCACGTGG-CTGCCTAAG-3’. DNA templates were
denatured at 95°C for 3 min, and then each PCR was
subjected to 35 cycles, each consisting of 30 seconds of
denaturation at 95°C, 0.5 min of annealing at 63°C, and
45 seconds of extension at 72°C. The PCR products
were digested at 37°C for 3 h with 10 U of Hin-1
(NlaIII) endonuclease (Fermentase Canada). The frag-
ments were separated by electrophoresis on a 1.5% agar-
ose gel. “T” allele was in two fragments of 215 and
70 bp, while the uncut “C” allele had 285 bp.
Statistical Analysis
Qualitative variables were presented as raw count and
percentage. Mean± standard deviation was used for the
presentation of quantitative variables. Because of the
non-normal distribution of the data statistical analysis
were done using the non-parametric Kruskal-Wallis
One-Way Analysis of Variance and post hoc analysis
was performed by the Dunn procedure for pair wise
comparison. Allele frequency was computed with the
Powermaker program [42]. A P-value of less than 0.05
was considered statistically significant.
Results
We investigated the frequency and phenotypic associa-
t i o n so ft h eT a q 1 Ba n d- 5 1 4C / Tp o l y m o r p h i s m si n
CETP and LIPC genes respectively in 252 (55.4%)
women and 203 (44.6%) men with the mean age of
55.8 ± 11.2. Table 1 summarizes the demographic and
biochemical characteristics of all the subjects as well as
in each sex group separately. Women had significantly
higher levels of BMI, TC, HDL-C, LDL-C and MDA
than men (p = 0.001). TG was similar in both sexes.
CETP Taq1B polymorphism frequency and its
relation with the serum lipids
As demonstrated in Table 2, heterozygote subjects with
51.0% frequency were the most common genotype,
followed by B1B1 (28.4%) and B2B2 (20.6%) variants.
This prevalence was similar in both sexes (data not
shown).
B2 homozygote subjects had significantly higher
means of serum total cholesterol than B1B1 genotype.
Statistically significant difference was also found in the
serum HDL-C levels among different genotypes of
Taq1B polymorphisms with the highest level noted in
B2B2 subjects followed by B1B2 and B1B1 (P =0 . 0 1 ) .
Polymorphism at this locus, however, had no association
with the LDL-C and TG levels in all the participants.
Only in male subjects, however, LDL-C level was signifi-
cantly higher in B2B2 subjects than B1B1 genotype (132
vs. 111 mg/dl, P = 0.011). Serum TG level was also
higher in B2B2 male subjects than B1B2 (214 vs. 186
mg/dl, P = 0.041) (Data not shown). MDA, as a marker
for lipid peroxidation, was not significantly different
between the three genotypes.
Table 3 shows the comparison between the carriers
for each “B1” and “B2” alleles with non carriers. “B1”
carriers, had lower levels of TC, HDL-C and MDA (P =
0.005, 0.009 and 0.031, respectively) than non carriers.
The means for all the serum lipids, including the HDL-
C, were higher in “B2” allele carriers than non carriers
but this difference was not statistically significant.
LIPC polymorphism frequency and its association with
serum lipids
The most common form of the -514C/T polymorphism
in LIPC gene was CC with 74.4% prevalence followed by
CT and then TT genotype that was found only in 11
subjects (Table 4). In all the subjects no significant dif-
ferences were found in TC, LDL-C, TG and MDA
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morphism. The highest level of HDL-C was found in
TT genotype followed by CT and then CC (TT>CT >
CC). But this difference was significant only in female
participants between the heterozygote subjects and “C”
homozygotes (41 vs. 38 mg/dl, P = 0.021). (Data not
shown)
To assess the effect of the “T” allele on serum lipid
levels, 117 carriers of this allele were compared with
338 non-carriers (CC genotype) (Table 5). This analysis
showed higher HDL-C level in “T” carriers than CC
subjects (37.7 vs. 35.7 mg/dl, P = 0.047). No other asso-
ciation was found for “T” or “C” allele carriers.
Discussion
To explore the potential genetic aspects of the high pre-
valence of low HDL-C levels in the populations of Teh-
ran, we compared the serum lipids in different
genotypes of the CETP Taq1B and LIPC polymorphisms
in 455 residents of Tehran. The frequency of the CETP
“B2” allele in this study was 46.1% which is higher than
the 38.21% previously found by Daneshpour et al.[43] in
ag r o u po fT e h r a n ’s residents. However, it is in accor-
dance with the prevalence of 42% that was reported in
White and East Asian populations[44]. In comparison to
B1B1 genotype, B2 hetero and homozygote subjects had
respectively 2.26% and 7.36% higher levels of HDL-C.
This positive role is in agreement with the results of the
two other studies carried in Iran [43,45]. Thompson et
al. in their meta- analysis study, that covers the results
of 92 studies in different ethnic groups with more than
113,000 subjects, have also found a 4.5% increase in
HDL-C levels and a 0.9% and 2% decrease in LDL-C
and TG levels respectively for each inherited B2 allele
[44]. But, similar to Daneshpour et al[43], in the whole
population of our participants we did not find any sig-
nificant difference in the serum levels of LDL-C and TG
between different genotypes of CETP Taq1B
polymorphism.
In comparison to B2B2 subjects, lower means of TC
and HDL-C in “B1” allele carriers by 7.5% and 5.8%
respectively, shows the negative role of “B1” allele on
the TC and HDL-C level.
The frequency of “T” allele in this study group was
14.0% and only 11 subjects (6 men and 5 women) were
found with TT genotype. No comparable data was avail-
able for the prevalence of LIPC gene polymorphism in
Iran. However, in comparison to the prevalence of “T”
allele in 20 other studies in different ethnic groups,
summarized by Isaac et al.[17], the frequency of “T”
allele in our participants was the lowest, in particular as
compared with that of East Asian population. However,








Percent 100 44.6 55.4
Age(year) 55.8 ± 11.2* 58.0 ± 11.7 54.0 ± 10.4 0.001
BMI, (Kg/m
2) 28.0 ± 4.7 26.1 ± 3.6 29.5 ± 5.0 0.001
TC, (mg/dl) 203.2 ± 40.5 192.8 ± 37.2 211.5 ± 41.2 0.001
HDL,(mg/dl) 36.2 ± 8.8 33.3 ± 8.0 38.6 ± 8.7 0.001
LDL, (mg/dl) 128.4 ± 32.9 121.2 ± 30.8 134.3 ± 33.5 0.001
TG, (mg/dl) 200.0 ± 112.6 197.0 ± 115.2 202.5 ± 110.5 0.599
Malondialdehyde, (nmol/mL) 4.6 ± 1.8 4.2 ± 1.9 4.8 ± 1.8 0.001
*Values are expressed as mean ± SD









Prevalence, (%) 20.6 51.0 28.4
Total cholesterol, (mg/dl) 215.2 ± 44.1*† 202.2 ± 39.0 196.6 ± 39.3 0.011
HDL cholesterol, (mg/dl) 37.9 ± 7.4‡ 36.1 ± 9.0 35.3 ± 9.6 0.017
LDL cholesterol, (mg/dl) 135.7 ± 33.2 128.2 ± 32.0 123.3 ± 33.5 0.088
Triglyceride, (mg/dl) 209.2 ± 123.6 201.3 ± 115.0 191.0 ± 99.5 0.227
Malondialdehyde, (nmol/mL) 5.0 ± 2.1 4.5 ± 1.7 4.4 ± 1.8 0.084
*Values are expressed as mean ± SD
† Shows significant difference between B2B2 and B1
‡Shows significant difference between B2B2 genotype with both B1B2 and B1B1
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confirm this finding. Although not statistically signifi-
cant, the approximately 15.2% lower level of HDL-C in
“C” carriers than non carriers is a notable difference.
Besides, HDL-C level was 5.3% higher in 117 carriers of
“T” allele than 338 non carriers. This is in agreement
with the common findings of the other studies relating
“T” allele to higher HDL-C level and lower enzyme
activity [11,17,21,46].
Considering the protective action of HDL-C against
LDL-C peroxidation [47] and the roles of CETP and HL
enzymes in the metabolism of HDL-C, MDA - as a pre-
sumptive marker of oxidant-mediated lipid peroxidation
- was compared among different genotypes. However,
lack of any association between MDA level and genetic
polymorphisms might be justified by the need to a more
sensitive and direct method for the measurement of
lipid peroxidation.
The major limitations of this study includes its cross
sectional nature, an absence of data regarding the habi-
tual dietary intake and physical activity of the subjects,
no measurement of the CETP and HL enzymes activity
and the sample size.
In summary, our study demonstrated a significant asso-
ciation between Taq1B polymorphism in CETP gene and
HDL-C variability with the highest HDL-C levels found in
“B2” homozygotes. “B1” allele of CETP was also related to
the lower levels of HDL-C. Conversely, higher means of
HDL-C was found in the “T” allele carriers of -514 C/T
polymorphism in LIPC gene. MDA level was not associated
with these two polymorphisms. However, studies with lar-
ger sample sizes are needed to confirm these findings.
Table 3 Comparison of biochemical variables in CETP “B1” and “B2” allele carriers with non carriers
“B1” Allele “B2” Allele
Variable B1 (+) B1 (-) P Value B2 (+) B2 (-) P Value
Number 361 94 326 129
Total cholesterol, (mg/dl) 200.1 ± 39.0* 215.2 ± 44.1 0.005 205.8 ± 40.8 196.6 ± 39.3 0.054
HDL cholesterol, (mg/dl) 35.8 ± 9.1 37.9 ± 1.4 0.009 36.6 ± 8.4 35.3 ± 9.6 0.055
LDL cholesterol, (mg/dl) 126.4 ± 32.6 135.7 ± 33.2 0.051 130.4 ± 32.5 123.3 ± 33.5 0.107
Triglyceride, (mg/dl) 197.6 ± 109.6 209.2 ± 123.6 0.258 203.6 ± 117.3 191.0 ± 99.5 0.510
Malondialdehyde, (nmol/mL) 4.5 ± 1.1 5.0 ± 2.1 0.031 4.6 ± 1.9 4.4 ± 1.8 0.224
*Values are expressed as mean ± SD









Prevalence, (%) 2.4 23.2 74.4
Total cholesterol, (mg/dl) 218.0 ± 48.0* 205.0 ± 43.0 202.0 ± 40.0 0.150
HDL cholesterol, (mg/dl) 42.0 ± 11.0 37.0 ± 10.0 36.0 ± 8.0 0.062
LDL cholesterol, (mg/dl) 135.0 ± 42.0 127.0 ± 36.0 129.0 ± 32.0 0.413
Triglyceride, (mg/dl) 225.0 ± 102.0 211.0 ± 123.0 196.0 ± 109.0 0.290
Malondialdehyde, (nmol/mL) 5.2 ± 1.6 4.7 ± 2.0 4.5 ± 1.8 0.312
*Values are expressed as mean ± SD
Table 5 Comparison of biochemical variables in LIPC “C” and “T” allele carriers with non carriers










Number 444 11 117 338
Total cholesterol, (mg/dl) 202.8 ± 40.3* 217.9 ± 47.9 0.093 206.6 ± 43.3 202.0 ± 39.5 0.163
HDL cholesterol, (mg/dl) 36.1 ± 8.7 41.6 ± 11.3 0.080 37.7 ± 10.1 35.7 ± 8.2 0.047
LDL cholesterol, (mg/dl) 128.2 ± 32.7 134.7 ± 42.2 0.206 127.6 ± 36.5 128.6 ± 31.7 0.956
Triglyceride, (mg/dl) 199.4 ± 112.9 225.0 ± 102.1 0.281 212.6 ± 120.9 195.6 ± 109.4 0.231
Malondialdehyde, (nmol/mL) 4.6 ± 1.9 5.2 ± 1.6 0.137 4.7 ± 2.5 4.5 ± 1.8 0.454
*Values are expressed as mean ± SD
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